

Antwerp, 24 November 2014, 18h00 CET

Gimv successfully exits Prosensa

Today, Gimv sold its remaining stake in the Dutch listed biotech company Prosensa (ticker: RNA:US). Gimv supported the development of the company through subsequent financing rounds since its initial investment in December 2008.

This exit has resulted in an uplift on the last published equity value as per 30 September 2014 of EUR 8.5 million (EUR 0.33 per share). In total, Gimv realizes a money multiple of 4.6x on its historical investment cost, resulting in a return significantly higher than its long term average return.

ABOUT GIMV

Gimv is a European investment company with over three decades' experience in private equity and venture capital. Gimv is listed on NYSE Euronext Brussels. Gimv currently manages around 1.8 billion EUR (including third party funds) of investments in 75 portfolio companies, which jointly realise a turnover of more than EUR 6 billion and employ over 26,000 professionals.

As a recognized market leader in selected investment platforms, Gimv identifies entrepreneurial and innovative companies with high-growth potential and supports them in their transformation into market leaders. Gimv's four investment platforms are: Consumer 2020, Health & Care, Smart Industries and Sustainable Cities. Each of these platforms works with a skilled and dedicated team across Gimv's home markets of the Benelux, France and Germany and can count on an extended international network of experts.

More information on Gimv can be found on www.gimv.com.

For further information please contact:

Patrick Van Beneden, Partner Health & Care Gimv

T +32 3 290 21 36 – patrick.vanbeneden@gimv.com

Frank De Leenheer, Investor Relations & Corporate Communications Manager

T +32 3 290 22 18 – frank.deleenheer@gimv.com